Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: RXGOLF who wrote (27373)	1/12/1999 1:11:00 PM
From: Mudcat	Respond to of 32384

<What is everyone expecting in the way of price action when we do get Ontak and Panretin approvals?> Greg, I will take a guess and say we hit maybe $14 when the approvals come out but then slip back down into the $12-13 range afterward. I was hoping some new news would come out of the H&Q conference, but MEDSUNMAN's report indicates otherwise. The major news that came out appears to be bad news. The Targretin news about side effects, although not new news to this thread, does answer some of our concerns, and not positively I must say. I always considered Targretin to be the drug that would sky rocket Lgnd's price, now I guess its back to the drawing board for Lgnd and me. I need to reevaluate my holdings in Lgnd. Does anyone know if the predicted profit, now in 4Q, will be enough to make Lgnd profitable for the entire year?